Portfolio company
Arbor Biotechnologies
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
18 investors
Sectors
About
This company develops programmable gene-editing tools and genetic medicines to treat patients with liver and central nervous system diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Shape Therapeutics
The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.
EDITAS Medicine
The company develops CRISPR-based genome editing medicines to treat patients with serious genetic diseases, including blood disorders and inherited eye conditions.
Metagenomi
Metagenomi develops genome editing tools and genetic medicines for patients with genetic mutations.
Alia Therapeutics
The company develops gene editing medicines for patients with genetic diseases.
Aera Therapeutics
This biotechnology company develops delivery platforms for genetic medicines to treat various diseases for biopharmaceutical partners and patients.
Precision BioSciences
This company develops in vivo gene editing therapies for patients with genetic and infectious diseases using its proprietary ARCUS genome editing platform.
Immitra Bio
This company develops an in-vivo gene editing platform to provide off-the-shelf curative treatments for patients with rare genetic diseases.
Affinia Therapeutics
This company develops rationally designed gene therapies and viral vectors for patients with heart and central nervous system diseases.